South Africa has temporarily halted the introduction of the AstraZeneca vaccine after the study showed that it offers less protection against the variant

South Africa has temporarily halted the introduction of the AstraZeneca vaccine after the study showed that it offers less protection against the variant

During Sunday’s testimony, South African Health Minister Dr. Zweli Mkhize said the suspension would be temporary as scientists figure out how to deploy AstraZeneca vaccine more effectively. Mkhize said South Africa will press ahead with vaccines made by Pfizer / BioNTech and Johnson & Johnson.

Early data released on Sunday indicates that two doses of the Oxford / AstraZeneca Covid-19 vaccine provided “minimal protection” against mild and moderate Covid-19 from the variant first identified in South Africa.

The study, which has not yet been published, included about 2,000 volunteers with an average age of 31 years. About half of them got the vaccine and the other half got a placebo, which does nothing

Researchers said the virus neutralization against variant B.1.351 “significantly decreased” when compared to the previous coronavirus strain. New release. The vaccine’s effectiveness against severe Covid-19, hospitalization, and death has not been evaluated.

Details of the study, conducted by researchers from the University of the Witwatersrand in South Africa and others, as well as from the University of Oxford, were shared in a press release. Oxford said the results have been submitted for peer review and a preliminary version will be released soon.

In a statement Sunday, a spokesperson for AstraZeneca said the company is “working closely with the South African Department of Health on how best to support the assessment against severe disease for the B.1.351 variant, and to begin bringing this vaccine to South Africa. People must prove their success”.

The company believes its vaccine will still protect against severe disease from the new variant B.1.351, the statement said, especially when the dosing period is eight to 12 weeks.

READ  Finnish Prime Minister Sana Marin's portrayal of Trendi sparked a debate about sexism

In a previous statement, the company said it was working with the University of Oxford to adapt the vaccine against the B.1.351 variant so that it would be ready for delivery in the fall if needed.

Maria Van Kerkhove, WHO’s chief technical officer for Covid-19, said Sunday that the WHO Independent Vaccine Committee will meet on Monday to discuss the AstraZeneca vaccine and what the new study means for the future.

“Some preliminary studies indicate less efficacy. But again, these studies are not yet fully published,” Van Kerkhove said on CBS’s “Face the Nation”.

She added that it is important to have more than one safe and effective vaccine: “We cannot rely on only one product.”

Written By
More from Aygen Oswald

Saudi prince sharply criticizes Israel at the Bahrain summit

DUBAI, United Arab Emirates (AP) – A prominent Saudi prince harshly criticized...
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *